328 results about "Hyperlipidemia" patented technology

The invention provides a multi-source heterogeneous data integrated coronary heart disease accurate prediction method, which comprises the following steps: acquiring various physiological signals of a patient in real time, the physiological signals comprising ST segment change characteristics and basic cycle function parameters in electrocardiosignals, and obtaining a multi-source signal data set; according to the joint data set, analyzing instantaneous fluctuation characteristics of a vascular resistance index in a postprandial hyperlipemia window period, extracting a vascular resistance fluctuation amplitude from the instantaneous fluctuation characteristics, and if it is detected that the fluctuation amplitude exceeds a preset threshold range, marking the window as a high-risk time window; if the score value exceeds a preset threshold value, triggering a coronary heart disease early warning signal according to the comprehensive risk score value in combination with a feature mode of a coronary heart disease hidden period in historical data; and storing the current high-risk time window characteristics and the blood sugar and blood fat curve change trend through a triggered coronary heart disease early warning signal to obtain structured risk archive data.

A pharmaceutical composition comprising a first RNAi agent and a second RNAi agent, the first RNAi agent comprising one or more first and / or one or more first siRNA conjugates capable of inhibiting APOC3 mRNA; a second RNAi agent comprising one or more second siRNAs and / or one or more second siRNA conjugates capable of inhibiting PCSK9 mRNA; the weight ratio of the first RNAi agent to the second RNAi agent in the pharmaceutical composition is (10: 1)-(1: 10) based on the total amount of the siRNA and the siRNA group. The pharmaceutical composition and the treatment method can effectively treat and / or prevent diseases or symptoms related to hyperlipidemia.

The invention belongs to the technical field of gene editing, and discloses a base editor system and application. According to the invention, a heterologous peptide sequence is inserted into IscB protein, the obtained peptide embedded IscB is fused with deaminase or glycosylase to construct a base editor, and DNA base editing is carried out. According to the base editor system, the size limitation is overcome, and single AAV delivery is achieved; the editing efficiency is obviously improved; the broad-spectrum applicability is realized; the system optimization is more flexible; the method has efficient editing potential in vivo, and the off-target effect is reduced. The invention provides an important new strategy for hyperlipemia treatment and provides a basis for gene therapy of other hereditary diseases.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention discloses a lactobacillus mucus fermentation strain and application thereof, the lactobacillus mucus fermentation strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on February 21, 2025, and the preservation number is GDMCCNO: 65936. The feruloyl esterase is separated and screened from white sour soup in Kailing in southeast of Guizhou province, has feruloyl esterase activity, and shows good blood fat reducing and fatty liver treating capabilities in a HepG2 high-fat cell model and a high-fat zebra fish model. The compound has a good prospect in the development of products for preventing or treating hyperlipidemia and fatty liver and relieving obesity.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the technical field of health-care food, and particularly relates to a sacha inchi oil-based gel candy with functions of reducing hypertension, hyperglycemia and hyperlipidemia and a preparation method thereof, and the sacha inchi oil-based gel candy comprises the following components: 1) a main component: 30-70% of sacha inchi oil; 2) a blood fat reducing synergistic component which is one or a combination of more of 0.5%-5% of phytosterol, 0.1%-2% of a red yeast rice extract and 0.01%-0.5% of sugarcane octacosanol; 3) a hypoglycemic synergistic component, which comprises one or a combination of more of 5%-20% of inulin / fructo-oligosaccharide, 0.5%-5% of a bitter gourd extract, 0.5%-5% of a mulberry leaf extract and 10-200 [mu] g / grain of chromium; 4) an antihypertensive synergistic component, wherein the antihypertensive synergistic component is one or a combination of more of 500-5000FU / grain of nattokinase, 0.5-5% of a celery seed extract and 1-8% of a hawthorn extract; through scientific compounding, the sacha inchi oil and various synergistic components exert a combined effect, and meanwhile, auxiliary regulation is carried out on blood sugar, blood fat and blood pressure; the main components are derived from natural plant extracts or functional grease, so that the health-care product is high in safety and suitable for daily health care.

The invention provides application of qi and blood strengthening oral liquid in preparation of a medicine for improving hyperlipidemia, and belongs to the technical field of medicine preparations. According to the invention, the mass ratio relationship among the components and the preparation method thereof are researched, and especially in the preparation process, the traditional Chinese medicine components are extracted by means of high-pressure steam heating, vacuum concentration and the like under different pressures in batches and stages, so that the obtained oral liquid for consolidating qi and blood is high in content of effective components, and has a good effect on consolidating qi and blood. The oral liquid for consolidating qi and blood can significantly improve hyperlipidemia, and has potential clinical application value.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating glycolipid metabolic diseases and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15-19 parts of coptis chinensis, 10-15 parts of rhodiola rosea, 10-20 parts of gynostemma pentaphylla, 9-12 parts of kapok, 10-15 parts of soapberry, 9-15 parts of salvia miltiorrhiza, 10-15 parts of rhizoma alismatis, 9-12 parts of oriental wormwood, 9-12 parts of radix bupleuri, 5-10 parts of semen cassiae, 10-15 parts of rhizoma anemarrhenae, 10-15 parts of hawthorn, 6-9 parts of polygonum cuspidatum and 5-10 parts of fructus aurantii. The traditional Chinese medicine composition disclosed by the invention has the effects of inhibiting hyperlipidemia, hyperglycemia and hepatic lipid accumulation and relieving insulin resistance, and has a remarkable curative effect on relieving and treating glycolipid metabolic diseases.

The present invention provides a pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia. According to the present invention, compartments comprising a drug are formulated in separate forms so as to solve problems related to the dissolution and absorption of the drug due to drug interaction, and a biologically equivalent preparation can be obtained when compared to conventional single preparation.

The invention relates to a bezafibrate-atenolol crystal compound as well as preparation and application thereof. Specifically, the invention discloses a bezafibrate-atenolol crystal compound, and the bezafibrate-atenolol crystal compound has the advantages that the solubility of bezafibrate is obviously improved, the pharmacokinetic performance is obviously improved, and the lipid-lowering effect is obviously improved. The invention also discloses preparation of the crystal compound and application of the crystal compound in prevention and / or treatment of hyperlipidemia.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents such as small interfering RNA (siRNA) molecules, able to inhibit proprotein convertase subtilisin kexin 9 (PCSK9) gene expression. Also disclosed are pharmaceutical compositions that include PCSK9 RNAi agents and methods of use thereof. The PCSK9 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the PCSK9 RNAi agents in vivo provides for in vivo provides for inhibition of PCSK9 gene expression and thereby reduction of PCSK9 protein. The RNAi agents can be used in methods of treatment of diseases or disorders mediated at least in part by PCSK9 gene expression, including among others hypercholesterolemia, familial hypercholesterolemia including heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH), familial hypobetalipoproteinemia, hyperlipidemia, coronary artery disease, polygenic dyslipidemia, heart disease, cardiovascular disease (CVD) including clinical atherosclerotic cardiovascular disease (ASCVD).

The invention belongs to the field of functional food, health care products and medicines, and particularly relates to okra polysaccharide with a function of improving metabolic syndrome as well as a preparation method and application of the okra polysaccharide. The preparation method of the okra polysaccharide comprises the steps of pretreatment, alcohol soaking of raw materials, extraction of filtrate, alcohol precipitation, dialysis, concentration and freeze drying. The okra polysaccharide provided by the invention can improve metabolic syndrome indexes including obesity, hyperlipidemia, hyperglycemia, hypertension, liver inflammation, flora disorder and the like, the comprehensive improvement effect is better than that of commercial apple pectin, citrus pectin and inulin, and the okra polysaccharide can be used as prebiotics to enrich intestinal beneficial bacteria deficiency caused by metabolic syndrome. The sources of natural medicines and health-care products for preventing and treating the metabolic syndrome are widened.

The invention discloses a traditional Chinese medicine constitution identification method and device, a storage medium and a server. The method comprises the following steps: acquiring a human face spectrum sample and blood fat contents of a tested crowd; inputting the human face spectrum sample into a pre-constructed hyperlipidemia risk prediction model to obtain a target human face spectrum sample with hyperlipidemia in the tested crowd and a first target blood fat four-item content corresponding to the target human face spectrum sample; making corresponding labels on the basis of the target face spectrum samples, corresponding first target blood fat four-item contents and traditional Chinese medicine constitution categories, and training the model through training samples obtained by making the corresponding labels to obtain a traditional Chinese medicine constitution identification model; obtaining a to-be-detected human face spectrum sample, and inputting the sample into the traditional Chinese medicine constitution identification model to obtain the content of four second target blood lipids suffering from hyperlipidemia in the detected crowd and a traditional Chinese medicine constitution identification result corresponding to the content of the four second target blood lipids; the technical problem that enough support cannot be accurately provided for treatment and prevention of patients with the lipemia is solved.

The invention discloses a myocardial ischemia reperfusion injury animal model construction method and application thereof in the technical field of model animal preparation. The method comprises the steps of hypertension and hyperlipidemia pretreatment, standardized ischemia-reperfusion operation, immune microenvironment regulation and control and model evaluation and verification. According to the invention, model construction is carried out on an integrated model operation table, so that a standardized ischemia-reperfusion process is realized, reproducibility of a myocardial injury degree and an immune cell infiltration rule of the model is realized, and suitability of the model and nano-drug research is enhanced; and a reliable tool is provided for research and development of targeted drugs such as immune cell membrane coated nanoparticles.

The invention mainly relates to a composition for reducing fat and losing weight as well as a preparation method and application thereof, and belongs to the technical field of biology. The composition comprises 30-60 parts of cordyceps flower sporocarp particles, 5-20 parts of morchella sporocarp particles, 10-25 parts of tartary buckwheat powder, 10-25 parts of a mulberry leaf water extract, 5-21 parts of a rhizoma polygonati water extract and 1-6 parts of a cassia seed water extract. The raw materials are mixed to obtain the composition. The composition can improve the blood fat level of hyperlipidemia, inhibit weight increase, reduce the volume of white fat cells, inhibit liver lipid deposition, reverse liver tissue and liver function damage, effectively reduce lipid and lose weight, and play a role in treating hyperlipidemia, obesity and fatty liver.

The present invention belongs to the technical fields of glycoprotein preparation and biomedicine, and particularly relates to a Stropharia rugosoannulata glycoprotein extract, a preparation method thereof and an application thereof. The present invention firstly proposes a method for extracting Stropharia rugosoannulata glycoprotein. Compared with the conventional alkali solution-acid precipitation method for extracting plant glycoproteins, the extraction method of the present invention has a higher glycoprotein yield. The contents of protein and polysaccharide in the extracted Stropharia rugosoannulata glycoprotein extract are both relatively high, especially the polysaccharide content is significantly higher than that of the alkali solution-acid precipitation method. Furthermore, the extracted Stropharia rugosoannulata glycoprotein has excellent hypolipidemic and antioxidant activities and can be used for the treatment of hyperlipidemia. At the same time, the method for extracting Stropharia rugosoannulata glycoprotein of the present invention has a simple process, is easy to control, and is suitable for industrial production.

The invention discloses a medicinal and edible traditional Chinese medicine solid beverage for preventing and treating gout and reducing hypertension, hyperglycemia and hyperlipidemia, which comprises 25 medicinal and edible raw materials such as 20-30 parts of chrysanthemum, 15-20 parts of hawthorn and the like, preferably 25 g of chrysanthemum, 35 g of kudzuvine root and the like. The preparation method comprises the following steps: screening, washing, drying, processing by an ancient method, crushing, sieving by a 120-300-mesh sieve, mixing to prepare a material A, and processing into a bag or granular beverage. The beverage is free of toxic and side effects, free of saccharides and chemical additives, and capable of preventing and treating gout and'four highs', promoting excretion and metabolism of uric acid and enhancing immunity; the traditional Chinese medicine composition can soften heart and cerebral vessels, reduce carotid plaques, prevent thrombus and prevent cardiovascular and cerebrovascular diseases, has health-care and health-preserving effects, and is remarkable in curative effect through experimental verification.

Disclosed herein are compositions and methods for the modulation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) expression, wherein the compositions include an siRNA duplex or a conjugated siRNA duplex. Also disclosed herein are methods, and compositions for use in methods, of treating age-related macular degeneration (AMD) or hyperlipidemia. The compositions disclosed herein comprise an siRNA duplex that comprises a sense sequence and an antisense sequence, wherein the sense sequence and the antisense sequence are at least partially complementary to each other.

The present application discloses a lactoferrin-modified liposome, a preparation method thereof and an application thereof. The liposome is loaded with Gastrodia elata active substances, and the Gastrodia elata active substances include barisonoside H, barisonoside K and barisonoside W. Through in vitro experiments and characterization, it is found that the liposome has a smoother drug release performance and drug loading performance for Gastrodia elata active substances after being modified with lactoferrin. The liposome has application prospects in related health fields such as hyperlipidemia and improvement of intestinal flora.

The application discloses a glucagon peptide-1 and glucagon receptor dual-agonistic polypeptide and application thereof, and the polypeptide structure is shown in the following general formula (I). The dual-agonistic polypeptide has dual-agonistic activity on human GLP-1 and glucagon receptors. The GLP-1 / glucagon receptor dual-agonistic polypeptide can effectively reduce blood sugar and weight, and has obvious lipid-regulating effect. The GLP-1 / glucagon receptor dual-agonistic polypeptide is stable in vivo, and is suitable to be used as an active component of drugs for diabetes, obesity, hyperlipidemia and the like.

The present invention discloses a golden chrysanthemum flavonoid glycoside derived from golden chrysanthemum, wherein the golden chrysanthemum flavonoid glycoside is apigenin 7-O-(6"-O-malonyl)-β-D-glucoside derived from golden chrysanthemum. The present invention separates and purifies apigenin 7-O-(6"-O-malonyl)-β-D-glucoside from golden chrysanthemum for the first time, completes the first synthesis through a 5-step synthesis process with a total yield of 2.7%, and discovers for the first time that the compound has activity in improving hyperlipidemia and fatty liver in vitro and in vivo. Therefore, the compound can be used in the preparation of products for treating related diseases such as hyperlipidemia and fatty liver.

The invention relates to a traditional Chinese medicine tea drink composition for treating obesity and hyperlipidemia. The composition is prepared from the following raw material medicines in parts by weight: 4-8 parts of roses, 4-8 parts of lotus leaves, 4-8 parts of pericarpium citri reticulatae, 8-12 parts of cassia seeds, 8-12 parts of raw hawthorn fruits, 8-12 parts of radix salviae miltiorrhizae and 2-6 parts of seville orange flowers. The invention further provides application of the traditional Chinese medicine tea drink composition. The whole formula integrates the functions of promoting digestion, removing food stagnation, promoting diuresis, activating blood, promoting the circulation of qi and relieving depression, treats both symptoms and root causes, is mild in nature, does not hurt healthy qi, and is suitable for people with phlegm-damp constitution, qi stagnation and blood stasis type obesity and hyperlipidemia to drink as tea.

This invention discloses a fermented traditional Chinese medicine for treating hyperlipidemia, its preparation method, and its application, relating to the field of traditional Chinese medicine. This fermented traditional Chinese medicine is prepared using Bacillus sp. JQ.Y-1, which was deposited on June 24, 2021, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M2021761. The fermented traditional Chinese medicine provided by this invention offers a new alternative drug for the treatment of hyperlipidemia of the dampness-obstruction type in the middle jiao (middle burner). It has a significant lipid-lowering effect, is safe and reliable, can regulate intestinal flora, protect the liver and kidneys, and has no side effects.

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

The invention discloses white paeony root polysaccharide with a blood fat reducing function as well as a preparation method and application of the white paeony root polysaccharide. The radix paeoniae alba polysaccharide with the blood fat reducing function is extracted from radix paeoniae alba for the first time, and cell experiments prove that the polysaccharide has the effect of reducing lipid generation in a high-fat cell model; further animal model experiments prove that the polysaccharide can also achieve the blood fat reducing effect in a hyperlipidemia animal model, it is proved that the polysaccharide can be used for preparing the blood fat reducing medicine, and the polysaccharide belongs to natural ingredients and is high in safety and wide in application prospect.

The invention provides antisense oligonucleotide aiming at a Sptbnl target spot and application of the antisense oligonucleotide. The antisense oligonucleotide can be used for knocking down the expression of Sptbnl, and in-vivo and in-vitro experiments find that the antisense oligonucleotide can be used for treating hyperlipidemia and NASH and can also be used for treating neovascular eye diseases.

The present invention relates to a composite probiotic for preventing, alleviating or treating hyperlipidemia, wherein the composite probiotic comprises Bifidobacterium animalis subsp. lactis with a preservation number of GDMCC No: 65455. Bifidobacterium animalum subsp.lactis C‑2 strain and Lactobacillus fermentum with the deposit number CGMCC No.28336 Lactobacillus fermentum GLF-217 strain. There is a potential interaction between the two strains, which can cooperate with each other and enhance synergy. The combination of the two strains significantly improves the effect of preventing, alleviating or treating hyperlipidemia. Specifically, it can significantly reduce body weight and fat content, improve blood sugar and blood lipid levels, regulate immunity and increase antioxidant levels, regulate adipose tissue metabolism, and improve gastrointestinal short-chain fatty acid metabolism.

The embodiment of the invention provides a traditional Chinese medicine preparation for improving three-high constitution and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw materials: 1-6 parts of fructus lycii, 2-10 parts of radix puerariae, 2-9 parts of fructus crataegi, 1-3 parts of rhizoma gastrodiae, 0.5-2 parts of radix notoginseng, 0.5-3 parts of radix salviae miltiorrhizae, 1-5 parts of flos chrysanthemi, 1-3 parts of pericarpium citri reticulatae, 2-9 parts of semen coicis, 1-3 parts of herba menthae, 1-5 parts of folium mori and 1-6 parts of flos lonicerae. Therefore, the medicinal and edible dual-purpose beverage with the effects of tonifying spleen and promoting the circulation of qi, clearing damp and burning fat, reducing phlegm and dredging collaterals, and promoting blood circulation to remove blood stasis is obtained, is a medicinal and edible and broad-spectrum product for preventing and improving physique, and is widely applicable to people with hyperlipidemia, hypertension, hyperglycemia and the like.